Latest news with #Vilnius
Yahoo
a day ago
- Business
- Yahoo
Notice on the General Meeting of Shareholders of the AUGA group, AB entity under restructuring on 12 August 2025 to approve the Company's draft restructuring plan
AUGA group, AB entity under restructuring (code 126264360, registered office at Konstitucijos pr. 21C, Vilnius, hereinafter referred to as the 'Company'), by the initiative and decision of the Board, is convening a General meeting of shareholders on August 12, 2025, at 10:00 a.m., where the Company's shareholders will vote on the approval of the Company's draft restructuring plan, hereinafter referred to as the 'Meeting'. The Meeting will be held at the conference room at the business center QUADRUM NORTH, address Konstitucijos ave. 21C, Vilnius. The registration of the shareholders begins at 10.00 a.m. Only those persons who will be shareholders of the Company at the close of the record date of the Meeting may participate and vote at the Meeting. The record date of the Meeting shall be 5th August 2025. Agenda of the Meeting: 1. Approval of the Company's draft restructuring plan Attached to this announcement is the restructuring plan prepared by the Company, which outlines economic, technical, organisational, and other measures to overcome the Company's financial difficulties. The goals of the restructuring plan (i.e. the settlement with creditors and the improvement of financial results at the group level) will be achieved through the following strategic actions: Separation, development and sale of the dairy segment through the establishment of a Sustainable Diary Farming Fund initiated by the Group Sale of Land-Holding Companies Separation of 11.5 thousand ha of consolidated crop farming agricultural business into the Raseiniai Region Crop Growing Fund Sale of Baltic Champs, UAB shares Following the implementation of these strategic actions, it is anticipated that the Company and its controlled entities (hereinafter referred to as the 'Group') will fulfil all financial obligations to external creditors by 2029. The new business model will not only ensure the preservation of the Group's activities but also enhance its financial results, safeguarding the interests of creditors, shareholders, and the Company itself. Proposed draft decisions of the Meeting are the following: 1. Approval of the Company's draft restructuring plan 1. To approve the Company's draft restructuring plan in accordance with the attached draft. 2. To authorise the CEO and the Board of the Company (with the right to sub-delegate) to execute the accompanying documents and annexes necessary to prepare and attach to the Company's draft restructuring plan, and to take any other actions and execute any other documents necessary for the filing of the Company's draft restructuring plan with the Court. Shareholders of the Company shall have a right to participate and vote at the Meeting personally or by power of attorney or represented by the person with whom an agreement on the transfer of voting rights is concluded. The total number of the Company's shares of EUR 0.29 par value each and the number of shares granting voting rights during the Meeting is the same and amounts to 233,803,368. ISIN code of the Company's shares is LT0000127466. A person attending the general meeting of shareholders and having a voting right must provide a person's identification document. A person who is not a shareholder must additionally provide a document confirming his/her right to vote at the general meeting of shareholders. Each shareholder shall have a right in the manner established by the laws to authorise other (natural or legal) person to attend and vote at the general meeting of shareholders on his/her behalf. At the general meeting of shareholders an authorised person shall have the same rights as would be held by the shareholder represented by him/her, unless the authorized person's rights are limited by the power of attorney or by laws. The authorized person must provide a power of attorney certified in the manner established by laws. A power of attorney issued in a foreign state must be translated into Lithuanian and legalised in the manner established by laws. The Company does not establish special form of power of attorney. Shareholder shall have the right to authorize through electronic communication channels another person (natural or legal) to participate and vote in the meeting on shareholder's behalf. Such authorization shall not be approved by the notary public. The power of attorney issued through electronic communication channels must be confirmed by the shareholder with a safe electronic signature developed by safe signature equipment and approved by a qualified certificate effective in the Republic of Lithuania. The shareholder shall inform the Company on the power of attorney issued through electronic communication channels by e-mail info@ no later than until the last business day before the meeting. The power of attorney and notification shall be issued in writing. The power of attorney and notification to the Company shall be signed with the electronic signature but not the letter sent via e-mail. By submitting the notification to the Company, the shareholder shall include the internet address from which it would be possible to download free of charge software to verify an electronic signature of the shareholder. A shareholder or a person authorised by him/her shall have a right to vote in writing in advance by filling in the general ballot paper. Form of the general ballot paper to vote in this meeting shall be provided together with publishing the last update to the notice not later than by 10 days prior to the general meeting date. Upon a shareholder's request, the Company, not later than 10 days before the general meeting, shall send the general ballot paper by registered mail free of charge. The general ballot paper shall also be provided on the Company's website at not later than by 10 days prior to the general meeting date. The filled-in general ballot paper and the document confirming the voting right (if any) must be submitted to the Company sending by registered mail or providing them against signature at the address of the registered office of the Company indicated in the notice and received by the Company not later than on the last business day until the meeting. The Company is not providing the possibility to attend and vote at the general meeting of shareholders through electronic means of communication. The shareholders holding shares that grant at least 1/20 of all votes shall have the right of proposing to supplement the agenda of the general meeting of shareholders. Draft decisions on the proposed issues shall be submitted together with the proposal or, if the decisions do not need to be approved, explanations on each proposed issue of the general meeting of shareholders shall be presented. Proposal to supplement the agenda must be presented to the Company sending them by registered mail or providing it against signature at the address of the registered office of the Company indicated in the notice. The agenda will be supplemented, if the proposal is received not later than 14 days before the general meeting of shareholders. Each shareholder holding shares that grant at least 1/20 of all votes at any time before the general meeting of shareholders or during the meeting shall have the right of proposing draft resolutions on the issues already included or to be included in the agenda of the general meeting of shareholders. The proposed draft decisions must be presented in writing sending them by registered mail or providing them against signature at the address of the registered office of the Company indicated in the notice. The shareholders shall have the right to present questions related to the agenda issues of the general meeting of shareholders to the Company in advance in writing, by providing the shareholder's personal identification number and consent to process personal data – personal identification number in the letter which should be sent to the Company by registered mail or delivered against signature. The Company undertakes to respond if questions are received not later than 3 business days before the general meeting of shareholders. Responses of a general character shall be posted on the Company's website The Company will not respond personally to the shareholder, if the respective information is posted on the Company's website. The shareholders could get familiarised with the documents possessed by the Company related to the agenda of the meeting, including notification on convocation of the meeting, information about the total number of the Company's shares and the number of shares granting voting rights during the general meeting of shareholders, draft resolutions, and other documents to be submitted to the general meeting of shareholders as well as to get information regarding execution of the shareholders' rights at AUGA group, RAB, at the address Konstitucijos ave. 21C, Vilnius, or on the Company's website at Contacts: CEO of AUGA group, AB under restructuring Elina Chodzkaitė – Barauskienė+370 5 233 5340 Attachment AUGA group restructuring plan with annexes (2025-06-20)(EN) (3)Sign in to access your portfolio
Globe and Mail
6 days ago
- Business
- Globe and Mail
BTCC Exchange Reports 132% Total Reserve Ratio with Ethereum Leading at 170% in July 2025
A Media Snippet accompanying this announcement is available by clicking on this link. VILNIUS, Lithuania, July 16, 2025 (GLOBE NEWSWIRE) -- BTCC, the world's longest-serving cryptocurrency exchange since 2011, has released its July 2025 Proof of Reserves (PoR) report, demonstrating a total reserve ratio of 132%. This marks the fourth consecutive month of maintaining reserves well above 100% since launching monthly PoR reporting in April 2025. The comprehensive report reveals strong asset backing across all major cryptocurrencies, with Ethereum showing the highest reserve ratio: Bitcoin (BTC): 120% Ethereum (ETH): 170% XRP: 145% Tether (USDT): 143% USD Coin (USDC): 110% Cardano (ADA): 120% These ratios demonstrate BTCC's commitment to maintaining sufficient reserves to fully back all user deposits, with Ethereum's 170% ratio highlighting particularly strong backing for the second-largest cryptocurrency by market capitalization. "July has been a remarkable month for the cryptocurrency market," said Alex Hung, Head of Operations at BTCC Exchange. "Rising geopolitical tensions and new US tariff policies have driven increased safe-haven demand, with Bitcoin breaking through the historic $120,000 milestone for the first time. Throughout this period of market volatility, BTCC has maintained its strong financial position while continuing to grow both our asset base and user community." Since launching monthly PoR reporting in April, BTCC has consistently maintained reserves above 100%, with ratios of 161% in April, 152% in May, and 135% in June. BTCC's Proof of Reserves system utilizes Merkle tree technology to provide cryptographic verification of platform reserves and user asset proof reports. This enables users to independently verify their assets and ensures complete transparency. As cryptocurrency markets continue to evolve, BTCC remains focused on providing a secure, reliable, and trustworthy trading environment for its global user base. The consistent maintenance of reserves above 100% demonstrates BTCC's unwavering commitment to user fund security and financial transparency. To view the complete July 2025 Proof of Reserves report and verify individual assets, please visit BTCC's website. About BTCC Exchange Founded in 2011, BTCC is one of the world's longest-serving cryptocurrency exchanges, offering secure and user-friendly trading services to millions of users globally. With a commitment to security, innovation, and community building, BTCC continues to be a trusted platform in the evolving cryptocurrency landscape.
Yahoo
15-07-2025
- Business
- Yahoo
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action VILNIUS, LT / / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB). Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-105 using the Pichia pastoris expression system. "With this partnership, we are establishing a robust and scalable production process for ATL- 105, laying the foundation for consistent quality for clinical development and commercial use," says Rüdiger Jankowsky, PhD, co-founder and CEO of AATec, and adds: "ATL-105 represents a new generation of inhaled biologics, combining anti-protease, anti-inflammatory, and antiinfective properties in one molecule. Delivered directly to the lungs, it enables fast, targeted action with minimal systemic exposure. We believe ATL-105 can redefine care in respiratory diseases with high medical need, such as non-CF bronchiectasis." "We are excited to support AATec in progressing towards clinical trials", shares Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech. "AATec is advancing a promising therapeutic solution addressing significant unmet medical needs, supported by a highly capable and dedicated team. With our decades of expertise in microbial systems, we are well-positioned to scale this program efficiently and deliver quality at every step." "We have recognized the opportunity to support a program that could meaningfully advance care for patients with respiratory diseases," adds André Markmann, PhD, VP of Business Development at Northway Biotech. "Inhaled protein therapies are gaining significant traction, and ATL-105 stands out as one of the most promising approaches in this area." AATec develops ATL-105 to treat NCFB, a chronic inflammatory respiratory condition which affects millions of people worldwide. This debilitating disease is marked by dilated bronchi, persistent inflammation, frequent airway infections and impaired mucus clearance. In addition to NCFB, ATL-105 has therapeutic potential for a broader range of inflammatory and infectious respiratory diseases, such as COPD, ARDS and other indications, reflecting the versatility of its anti-inflammatory, immunomodulatory, and anti-infective properties. About AATec Medical AG AATec Medical GmbH is a biotechnology company developing a product platform based on a novel recombinant version of alpha-1 antitrypsin (AAT) for the treatment of respiratory inflammatory diseases, airway infections and rare diseases. The company has successfully demonstrated proof-of-principle in several indications and is currently preparing for a proof-ofconcept clinical trial with the first product candidate ATL-105 for inhaled application in non-CF bronchiectasis. AATec was founded by a seasoned interdisciplinary team with long-standing experience in clinical research, biopharmaceutical development and product industrialization. For further information, please visit and follow AATec on LinkedIn. About Northway Biotech Northway Biotech is a leading CDMO specializing in protein-based biologics and gene therapies, offering comprehensive, end-to-end biopharmaceutical development and manufacturing services. With deep expertise in cell line development, process optimization, and cGMP manufacturing, Northway Biotech supports programs from early-stage development through to commercial production. Founded in 2004, the privately held company operates state-of-the-art facilities in Lithuania and the United States, delivering high-quality, compliant solutions tailored to each client's unique needs. For further information, please visit Northway Biotech Contact: Prof. Vladas Algirdas BumelisCEO and Chairman of the AATec Medical Contact: Dr. Rüdiger Jankowsky, CEOinfo@ Media Contact: MC ServicesKatja Arnold, Julia von Hummelaatec-medical@ Phone: +49 (0)89 2102280 SOURCE: Northway Biotech View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Russia Today
14-07-2025
- Business
- Russia Today
Germany becoming dangerous again
Germany is becoming 'dangerous again,' Kremlin spokesman Dmitry Peskov said on Monday, responding to remarks by German Defense Minister Boris Pistorius who proclaimed the readiness of the country's troops to kill Russian servicemen. Speaking to RBK business daily, Peskov said it was hard to believe that Pistorius actually made such statements. 'But, unfortunately, this is so,' he said. 'Germany is becoming dangerous again,' Peskov added. Pistorius made the warlike comments in an interview with the Financial Times published on Sunday, lauding the battle-readiness of German troops and their resolve to take lethal action against Russian forces if necessary. 'If deterrence doesn't work and Russia attacks, is it going to happen? Yes,' Pistorius said. 'But I would recommend that you simply go to Vilnius and talk to the representatives of the German brigade there. They know exactly what their job is.' Any talk about peace can only be possible 'on equal terms' and 'from a position of strength,' Pistorius insisted. While Berlin has not been seeking to 'intimidate anyone,' one should not 'think that we're weak or that we won't defend ourselves,' he added. The purported Russian threat has long been one of the key talking points for various officials from NATO countries. Moscow has repeatedly dismissed speculation that Russia plans to attack the US-led bloc as 'nonsense.' Last month, Peskov suggested that the bloc merely needs a 'monster' to justify its existence and ever-growing defense costs. 'They have made a monster out of Russia in order to justify the decision to increase NATO defense spending to 5% of GDP,' the Kremlin spokesman said at the time.
Russia Today
14-07-2025
- Politics
- Russia Today
EU state won't recognize Russian winners of marathon
Organizers of the Vilnius Marathon in Lithuania have barred Russian and Belarusian nationals from representing their countries in the standings and receiving awards, according to the event's press service. The race organizers have introduced special conditions for Russian and Belarusian participants: they must present a Lithuanian residence permit and submit a written declaration denouncing Russia's 'military actions." In addition, they are excluded from prize eligibility and cannot appear in the official standings under their nationalities. 'All athletes from Russia and Belarus agree that by participating in the event they are competing without competition and are not eligible for prizes or awards,' according to the Rules page of the marathon's official website. Russian and Belarussian athletes must also provide 'a freely signed document in English or Lithuanian expressing opposition to Russian hostilities,' reads another point. When asked by Russian media outlet Volna if targeting only Russian and Belarusian athletes constituted discrimination, the organizers dodged the question, saying that 'only Lithuanian citizens' are eligible for prizes because the race is part of the 'closed championship of Lithuania.' When asked whether the nationalities of athletes from other countries will be listed in the standings, the organizers confirmed that they will. The Vilnius Marathon is scheduled for September 14 and will feature multiple events, including a full marathon, half marathon, 10km, 5km, and a 200m children's race. Entry fees range from €15 to €65. Top prizes are worth up to €1,500 ($1,700). Since the Ukraine conflict escalated in February of 2022, Russian and Belarusian athletes have been banned from many international sporting events, with Western-led organizers citing 'solidarity with Ukraine.' Moscow has condemned the bans, accusing Western sports bodies of politicizing athletics. Lithuania and its Baltic neighbors, Estonia and Latvia, have long worked to sever cultural ties with Russia. Since the outbreak of the Ukraine conflict, these former Soviet republics have intensified this drive, which has been fueled by claims that Russia could attack the region coming from Western officials. In a recent security report, Lithuanian authorities named Russia, Belarus, and China as the country's main threats. Moscow, which denies any intention of attacking the Baltics, has accused the nations of harboring 'extreme Russophobia' and downgraded diplomatic ties with them in 2023.
